Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.
about
Pituitary somatostatin receptor signalingClinical importance of achieving biochemical control with medical therapy in adult patients with acromegalyThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyMeta-analysis on the effects of octreotide on tumor mass in acromegalyTumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.GENE THERAPY FOR THE TREATMENT OF PITUITARY TUMORSManagement of acromegaly in Latin America: expert panel recommendationsA novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms.Expert consensus document: A consensus on the medical treatment of acromegaly.ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsGamma knife radiosurgery for acromegaly.Medical therapy of acromegalyLong-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.Etiologic aspects and management of acromegaly.Resistance to somatostatin analogs in acromegaly: an evolving concept?Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.Pegvisomant in acromegaly: why, when, how.A consensus on the diagnosis and treatment of acromegaly complications.Copper-64 Radiopharmaceuticals for Oncologic ImagingReduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?Use of the metallothionein promoter-human growth hormone-releasing hormone (GHRH) mouse to identify regulatory pathways that suppress pituitary somatotrope hyperplasia and adenoma formation due to GHRH-receptor hyperactivation.Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.Illuminating somatostatin analog action at neuroendocrine tumor receptorsPatient-focussed outcomes in acromegaly.Multiple facets in the control of acromegaly.Octreotide LAR: safety and tolerability issues.Pharmacokinetic evaluation of lanreotide.Medical therapy in acromegaly.Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsOctreotide long-acting repeatable for acromegaly.Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission.Octreotide for acromegaly treatment: a reappraisal.Emerging drugs for acromegaly.Update on prognostic factors in acromegaly: Is a risk score possible?Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.The role of combination medical therapy in the treatment of acromegaly.
P2860
Q24631604-07199CF4-9163-4CDD-A818-C6A4454C56C5Q26741026-8B2CFE6B-102B-4D29-8B4D-CF80C8E6F389Q26796357-39FF7582-0210-438A-BDBA-410ED3BD448BQ28730120-21CD9375-2077-406D-BABE-B393B9171A47Q33564399-B9F3F780-8499-40F3-8509-8C2705DAD080Q33579615-4844A117-0E89-49AC-8395-250ADC79F44CQ33674877-1C3EA14F-D913-4FBA-B915-12AB496CA6B3Q33794388-92177A4F-1F4D-4383-9349-D8A6FAFDAE3AQ34130414-220F3BC8-7D76-4955-991A-249972BCAA11Q34406566-7B11C665-8604-43B4-A25C-B4D706C39CC6Q35009758-50E73CAF-6A62-4444-B372-51BFE3966D61Q35747137-867335F1-6DEE-4260-82BE-179FE16183BBQ35810502-CFD4D352-C815-4B4E-88CE-ABEE1B643BD6Q35895856-767052DF-E4DB-4845-B89B-152F2CF903F7Q35987482-D07743C1-5594-4576-8D74-7E11B2FC09EDQ35987499-A97A423B-B9E7-4202-83BA-EAB76F2A7C38Q36380875-5D934A78-A75A-4C3E-B7C2-6A9F9355C6C8Q36428225-017486A8-3D1E-4D5A-A899-070A73397D14Q36626503-F4793D3D-E4A5-4B79-AD1E-EF7D86960FDAQ36965612-5ADDDD12-7381-49A1-8883-F33DAE2BB150Q37061155-FB3DF8E7-5010-4864-8120-102A94980CFFQ37126530-0341B159-3EB4-4100-BB75-EA4EBF4D79C9Q37155476-B11A311F-A874-45AE-88A4-554FE6560355Q37244671-0FF0BD38-4BCD-42FA-A6B1-E88CB3262EACQ37321948-52F0E3B6-31CE-426A-8D1F-396A256F2FE0Q37443562-91E59710-8686-426F-A139-775EA8DC6F42Q37530996-3BD2029F-A13B-4282-AAEA-CA075E2EA341Q37531066-90F72867-B60F-4053-878D-9FBCF8A402C6Q37649647-67DFE8B5-8DAA-4922-AFB1-D8293B406F40Q37780553-ADA701FE-F25F-429B-BEFB-904C8141F909Q37859250-C74AE042-9E4D-4CAC-B629-1F79FDC3F7A3Q37980741-DC4E8F4E-5ACB-43AD-97A9-D90F379DE943Q37990556-D21EC5D6-9608-4473-9CDD-FCCC49E13CF7Q38062441-3FA52513-D754-4C96-99C9-9B572AFE5A8BQ38152458-3B3886CA-D7DA-4549-8341-EB774CA38ADDQ38176659-A2E5AA77-6104-4C3E-9B0A-260B2B42D3C2Q38214473-4BAC9907-7F27-417E-B762-84D610C1CD92Q38231413-CF9A3B4D-258A-46F4-A584-6FA90B5BC45BQ38246440-FD2AD544-D8D7-489A-8D51-E7F7877E6804Q38927318-23ED543C-497F-45E5-A1D1-8B52AD5F10FA
P2860
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.
@ast
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.
@en
type
label
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.
@ast
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.
@en
prefLabel
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.
@ast
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.
@en
P356
P1476
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.
@en
P2093
John S Bevan
P304
P356
10.1210/JC.2004-1093
P407
P577
2004-12-21T00:00:00Z